Conflict of Interest: Nothing to report.
Ofatumumab for refractory opsoclonus-myoclonus syndrome following treatment of neuroblastoma
Article first published online: 29 JUN 2013
Copyright © 2013 Wiley Periodicals, Inc.
Pediatric Blood & Cancer
Volume 60, Issue 12, pages E163–E165, December 2013
How to Cite
Ketterl, T. G., Messinger, Y. H., Niess, D. R., Gilles, E., Engel, W. K. and Perkins, J. L. (2013), Ofatumumab for refractory opsoclonus-myoclonus syndrome following treatment of neuroblastoma. Pediatr. Blood Cancer, 60: E163–E165. doi: 10.1002/pbc.24646
- Issue published online: 8 OCT 2013
- Article first published online: 29 JUN 2013
- Manuscript Accepted: 24 MAY 2013
- Manuscript Received: 11 FEB 2013
- opsoclonus-myoclonus syndrome;
Opsoclonus-myoclonus syndrome (OMS) may be associated with ANNA-1 (anti-Hu) autoantibodies. The standard treatment with IVIG, steroids, and anti-CD20 monoclonal antibody may fail, and optimal therapy is unknown. A patient developed OMS with high-titer ANNA-1 following recovery from neuroblastoma. She failed standard therapy and had only transient response to rituximab. Treatment with the humanized anti-CD20 monoclonal antibody ofatumumab combined with methotrexate resulted in transient neurologic improvement and decrease of ANNA-1. This suggests that ofatumumab combined with methotrexate should further be considered OMS patients, particularly in refractory disease. Pediatr Blood Cancer 2013;60:E163–E165. © 2013 Wiley Periodicals, Inc.